EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)Vergleichsstudie

Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer

Aditya Bardia, Xichun Hu, Rebecca Dent, Kan Yonemori, Carlos H Barrios, Joyce A O'Shaughnessy, Hans Wildiers, Jean-Yves Pierga, Qingyuan Zhang, Cristina Saura, Laura Biganzoli, Joohyuk Sohn iD und 8 weitere

New England Journal of Medicine · 05.12.2024 · 391 (22) · 2110-2122

DOI: 10.1056/nejmoa2407086 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 05.12.2024. Verfasst von Aditya Bardia und 19 weiteren Autor:innen. Beteiligte Einrichtung: From Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, and Massachusetts General Hospital, Boston, MA (A.B.); …. Hauptthemen laut MEDLINE: Antineoplastic Agents, Hormonal, Antineoplastic Agents, Immunological, Breast Neoplasms, Immunoconjugates. Die Arbeit wurde bisher 534-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: AstraZeneca and Daiichi Sankyo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Agents, HormonalAntineoplastic Agents, ImmunologicalBreast NeoplasmsImmunoconjugatesErb-b2 Receptor Tyrosine KinasesTrastuzumabAdultAgedFemaleHumansMiddle AgedAntineoplastic Combined Chemotherapy ProtocolsCamptothecinKaplan-Meier EstimateProgression-Free SurvivalReceptors, EstrogenAged, 80 and overTreatment Outcome

Substanzen

Antineoplastic Agents, HormonalAntineoplastic Agents, ImmunologicalCamptothecinImmunoconjugatesErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenTrastuzumabERBB2 protein, humantrastuzumab deruxtecan

Autor:innen und Institutionen

  • From Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, and Massachusetts General Hospital, Boston, MA (A.B.); the Department of Medical Oncology, Fudan University Shanghai Cancer C…

ORCID-Profile: Joohyuk Sohn, Giuseppe Curigliano

Förderung

  • AstraZeneca and Daiichi Sankyo

Zitieren

APA

Bardia, A., Hu, X., Dent, R., Yonemori, K., Barrios, C. H., O'Shaughnessy, J. A., Wildiers, H., Pierga, J. Y., Zhang, Q., Saura, C., Biganzoli, L., Sohn, J., Im, S. A., Lévy, C., Jacot, W., Begbie, N., Ke, J., Patel, G., Curigliano, G., & DESTINY-Breast06 Trial Investigators (2024). Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer. New England Journal of Medicine, 391(22), 2110-2122. https://doi.org/10.1056/nejmoa2407086

Vancouver

Bardia A, Hu X, Dent R, Yonemori K, Barrios CH, O'Shaughnessy JA, et al. Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer. New England Journal of Medicine. 2024;391(22):2110-2122. doi:10.1056/nejmoa2407086

BibTeX
@article{Bardia2024,
  author = {Bardia, Aditya and Hu, Xichun and Dent, Rebecca and Yonemori, Kan and Barrios, Carlos H and O'Shaughnessy, Joyce A and Wildiers, Hans and Pierga, Jean-Yves and Zhang, Qingyuan and Saura, Cristina and Biganzoli, Laura and Sohn, Joohyuk and Im, Seock-Ah and Lévy, Christelle and Jacot, William and Begbie, Natasha and Ke, Jun and Patel, Gargi and Curigliano, Giuseppe and DESTINY-Breast06 Trial Investigators, DESTINY-Breast06 Trial Investigators},
  title = {Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer},
  journal = {New England Journal of Medicine},
  year = {2024},
  volume = {391},
  number = {22},
  pages = {2110--2122},
  doi = {10.1056/nejmoa2407086}
}
Kostenlos starten →